Literature DB >> 19584295

Expression of an exogenous human Oct-4 promoter identifies tumor-initiating cells in osteosarcoma.

Padraic P Levings1, Sean V McGarry, Thomas P Currie, David M Nickerson, Steven McClellan, Steven C Ghivizzani, Dennis A Steindler, C Parker Gibbs.   

Abstract

We explored the nature of the tumor-initiating cell in osteosarcoma, a bone malignancy that predominately occurs in children. Previously, we observed expression of Oct-4, an embryonal transcriptional regulator, in osteosarcoma cell cultures and tissues. To examine the relationship between Oct-4 and tumorigenesis, cells from an osteosarcoma biopsy (OS521) were stably transfected with a plasmid containing the human Oct-4 promoter driving a green fluorescent protein (GFP) reporter to generate the transgenic line OS521Oct-4p. In culture, only approximately 24% of the OS521Oct-4p cells were capable of activating the transgenic Oct-4 promoter; yet, xenograft tumors generated in NOD/SCID mice contained approximately 67% GFP(+) cells, which selectively expressed the mesenchymal stem cell-associated surface antigens CD105 and ICAM-1. Comparison of the tumor-forming capacity of GFP-enriched and GFP-depleted cell fractions revealed that the GFP-enriched fractions were at least 100-fold more tumorigenic, capable of forming tumors at doses of <300 cells, and formed metastases in the lung. Clonal populations derived from a single Oct-4/GFP(+) cell were capable of forming tumors heterogeneous for Oct-4/GFP expression. These data are consistent with the cancer stem cell model of tumorigenesis in osteosarcoma and implicate a functional link between the capacity to activate an exogenous Oct-4 promoter and tumor formation. This osteosarcoma tumor-initiating cell appears highly prolific and constitutes a majority of the cell population in a primary xenograft tumor, which may provide a biological basis for the particular virulence of this type of cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19584295      PMCID: PMC2841219          DOI: 10.1158/0008-5472.CAN-08-3580

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

Review 1.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

Review 2.  Malignant bone tumors.

Authors:  C Parker Gibbs; Kristy Weber; Mark T Scarborough
Journal:  Instr Course Lect       Date:  2002

Review 3.  Applying the principles of stem-cell biology to cancer.

Authors:  Ricardo Pardal; Michael F Clarke; Sean J Morrison
Journal:  Nat Rev Cancer       Date:  2003-12       Impact factor: 60.716

4.  The intracellular distribution of the ES cell totipotent markers OCT4 and Sox2 in adult stem cells differs dramatically according to commercial antibody used.

Authors:  Patricia A Zuk
Journal:  J Cell Biochem       Date:  2009-04-01       Impact factor: 4.429

5.  Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery?

Authors:  Norman Jaffe; Humberto Carrasco; Kevin Raymond; Alberto Ayala; Farzin Eftekhari
Journal:  Cancer       Date:  2002-11-15       Impact factor: 6.860

6.  Prospective identification of tumorigenic breast cancer cells.

Authors:  Muhammad Al-Hajj; Max S Wicha; Adalberto Benito-Hernandez; Sean J Morrison; Michael F Clarke
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

7.  The clonal evolution of tumor cell populations.

Authors:  P C Nowell
Journal:  Science       Date:  1976-10-01       Impact factor: 47.728

8.  Oct4 distribution and level in mouse clones: consequences for pluripotency.

Authors:  Michele Boiani; Sigrid Eckardt; Hans R Schöler; K John McLaughlin
Journal:  Genes Dev       Date:  2002-05-15       Impact factor: 11.361

9.  Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro.

Authors:  Tatyana N Ignatova; Valery G Kukekov; Eric D Laywell; Oleg N Suslov; Frank D Vrionis; Dennis A Steindler
Journal:  Glia       Date:  2002-09       Impact factor: 7.452

10.  EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy.

Authors:  Walid A Osta; Yian Chen; Kaidi Mikhitarian; Michael Mitas; Mohamed Salem; Yusuf A Hannun; David J Cole; William E Gillanders
Journal:  Cancer Res       Date:  2004-08-15       Impact factor: 12.701

View more
  80 in total

Review 1.  Modeling sarcomagenesis using multipotent mesenchymal stem cells.

Authors:  Rene Rodriguez; Ruth Rubio; Pablo Menendez
Journal:  Cell Res       Date:  2011-09-20       Impact factor: 25.617

Review 2.  Moving from the laboratory bench to patients' bedside: considerations for effective therapy with stem cells.

Authors:  Lauren S Sherman; Jessian Munoz; Shyam A Patel; Meneka A Dave; Ilani Paige; Pranela Rameshwar
Journal:  Clin Transl Sci       Date:  2011-10       Impact factor: 4.689

3.  Perspective: Neuroregenerative Nutrition.

Authors:  Dennis A Steindler; Brent A Reynolds
Journal:  Adv Nutr       Date:  2017-07-14       Impact factor: 8.701

4.  Evidence for the osteosarcoma stem cell.

Authors:  C Parker Gibbs; Padraic P Levings; Steven C Ghivizzani
Journal:  Curr Orthop Pract       Date:  2011-07

Review 5.  The role of mesenchymal stem/progenitor cells in sarcoma: update and dispute.

Authors:  Jilong Yang; Zhiwu Ren; Xiaoling Du; Mengze Hao; Wenya Zhou
Journal:  Stem Cell Investig       Date:  2014-10-27

6.  Enrichment and characterization of cancer stem-like cells in ultra-low concentration of serum and non-adhesive culture system.

Authors:  Junfeng Zhang; Yunsheng Zhang; Lin Cheng; Chunlei Li; Lei Dai; Hui Zhang; Fenglian Yan; Hui Shi; Guanjun Dong; Zhaochen Ning; Wei Xu; Chuanping Si; Hongxin Deng; Huabao Xiong
Journal:  Am J Transl Res       Date:  2018-05-15       Impact factor: 4.060

Review 7.  Chemotherapy targeting cancer stem cells.

Authors:  Haiguang Liu; Lin Lv; Kai Yang
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

Review 8.  An overview of the role of cancer stem cells in spine tumors with a special focus on chordoma.

Authors:  Mojdeh Safari; Alireza Khoshnevisan
Journal:  World J Stem Cells       Date:  2014-01-26       Impact factor: 5.326

9.  SPAG9 is overexpressed in osteosarcoma, and regulates cell proliferation and invasion through regulation of JunD.

Authors:  Chi Xiao; Lin Fu; Chongnan Yan; Fenyong Shou; Qi Liu; Lei Li; Shaoqian Cui; Jingzhu Duan; Guoxin Jin; Jianhua Chen; Yuanming Bian; Xu Wang; Huan Wang
Journal:  Oncol Lett       Date:  2016-07-29       Impact factor: 2.967

10.  Smoothened as a new therapeutic target for human osteosarcoma.

Authors:  Masataka Hirotsu; Takao Setoguchi; Hiromi Sasaki; Yukihiro Matsunoshita; Hui Gao; Hiroko Nagao; Osamu Kunigou; Setsuro Komiya
Journal:  Mol Cancer       Date:  2010-01-12       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.